ASH 2023 | Nivolumab following CAR-T failure in R/R MM and NHL: results of a Phase II study
Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA, comments on the results of a Phase II study (NCT04205409) of nivolumab for the treatment of relapsed/refractory (R/R) hematological malignancies, including multiple myeloma (MM) and non-Hodgkin lymphoma (NHL), following CAR T-cell therapy (CAR-T) relapse. Dr Banerjee highlights the heterogeneous responses observed within the study population and emphasizes the need to determine the patients who would benefit from this treatment approach. This was the first prospective evaluation of nivolumab following CAR-T failure, and additional studies of this nature are necessary due to the limited treatment options available for patients with R/R multiple myeloma or NHL. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: SparkCures, Janssen, BMS, Genentech, Sanofi, Caribou, Pfizer
Research Funding: Pack Health
